Short course of R‐HyperCVAD/MTX/ARA‐C followed by ASCT as first‐line therapy in mantle cell lymphoma patients prolongs progression‐free survival to more than 9 years

Abstract

efforts should aim to improve access to care for all patients with MCL so that they can be evaluated for all available effective therapies.Keywords: autologous stem cell transplantation (ASCT); elderly; mantle cell lymphoma (MCL) SHORT COURSE OF R-HYPERCVAD/MTX/ ARA-C FOLLOWED BY ASCT AS FIRST-LINE